Volatile and intravenous anesthetics selectively attenuate the release of endothelium-derived hyperpolarizing factor elicited by bradykinin in the coronary microcirculation
- PMID: 8584052
- DOI: 10.1007/BF00168567
Volatile and intravenous anesthetics selectively attenuate the release of endothelium-derived hyperpolarizing factor elicited by bradykinin in the coronary microcirculation
Abstract
In addition to nitric oxide (NO) and prostacyclin (PGI2) another endothelium-derived factor, which hyperpolarizes vascular smooth muscle cell via activation of K+ channels, contributes to the vasorelaxant effect of bradykinin in different vascular beds. Preliminary findings suggest that this endothelium-derived hyperpolarizing factor (EDHF)-mediated vasodilatation is attenuated by both volatile and intravenous anesthetics. Since EDHF may play an important role in the coronary microcirculation, we investigated the effects of isoflurane (2 vol.% equivalent to approximately 250 microM), etomidate (30 and 100 microM), phenobarbital (100 microM) and thiopental (30 and 100 microM) on the EDHF-mediated dilator response to bradykinin and on the endothelium-independent dilatation evoked by sodium nitroprusside (SNP) in the isolated saline-perfused rat heart (Langendorff preparation). None of the anesthetics tested affected the dilator response to bradykinin or SNP under basal conditions. However, following inhibition of NO and PGI2 formation with NG-nitro-L-arginine (100 microM) and diclofenac (1 microM) respectively, isoflurane, etomidate and thiopental, but not phenobarbital, significantly attenuated the NO/PGI2-independent, i.e. EDHF-mediated dilator response to bradykinin, while the vasorelaxant effect of SNP remained unaffected. Isoflurane, etomidate and thiopental, but not phenobarbital, display cytochrome P450-inhibiting properties, suggesting that these anesthetics impair the cytochrome P450-dependent synthesis of EDHF in the coronary microcirculation.
Similar articles
-
Display of the characteristics of endothelium-derived hyperpolarizing factor by a cytochrome P450-derived arachidonic acid metabolite in the coronary microcirculation.Br J Pharmacol. 1994 Dec;113(4):1548-53. doi: 10.1111/j.1476-5381.1994.tb17172.x. Br J Pharmacol. 1994. PMID: 7889312 Free PMC article.
-
Etomidate and thiopental inhibit the release of endothelium-derived hyperpolarizing factor in the human renal artery.Anesthesiology. 1996 Jun;84(6):1485-8. doi: 10.1097/00000542-199606000-00025. Anesthesiology. 1996. PMID: 8669690
-
An endothelium-derived hyperpolarizing factor distinct from NO and prostacyclin is a major endothelium-dependent vasodilator in resistance vessels of wild-type and endothelial NO synthase knockout mice.Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9747-52. doi: 10.1073/pnas.97.17.9747. Proc Natl Acad Sci U S A. 2000. PMID: 10944233 Free PMC article.
-
Cytochrome P450 2C is an EDHF synthase in coronary arteries.Trends Cardiovasc Med. 2000 May;10(4):166-70. doi: 10.1016/s1050-1738(00)00065-7. Trends Cardiovasc Med. 2000. PMID: 11239797 Review.
-
Is EDHF an epoxyeicosatrienoic acid?Trends Pharmacol Sci. 2000 Apr;21(4):121-4. doi: 10.1016/s0165-6147(00)01445-0. Trends Pharmacol Sci. 2000. PMID: 10740282 Review. No abstract available.